|
N3C Privacy-Preserving Record Linkage
|
Resource Development
|
ASPE, CMS
|
NCATS
|
Privacy-preserving record linkage (PPRL) significantly expands the scope of secure patient-level data for N3C and unlocks exciting new opportunities for clinicians, rearchers, and patients to better understand COVID-19. Users sign A Linkage Honest Broker Agreement (LHBA) and use de-identified tokens to get information from N3C. PPRL protects patient privacy, enhances accuracy, and enables diverse insights.
|
|
Nanotechnology Characterization Laboratory
|
Resource Development
|
FDA
|
NCI
|
Collaboration Type: Also Research Initiative The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the preclinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers and facilitates the development and translation of nanoscale particles and devices for clinical applications.
|
|
Nanotechnology Environmental and Health Implications (NEHI) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, CDC, FDA
|
NIEHS
|
Nanoscale Science, Engineering, and Technology (NSET) subcommittee of the National Science and Technology Council charged NEHI with supporting Federal activities to protect public health and the environment. The NSET Subcommittee’s NEHI Working Group provides a forum for focused interagency collaborations on nanotechnology EHS and leadership in establishing the national nanotechnology EHS research agenda, in addition to communicating EHS information among NNI agencies and to the public. Specifically 1) Providing for information exchange among Federal agencies that support nanotechnology research and Federal agencies responsible for regulation and guidelines related to nanomaterials and products containing nanomaterials; 2) Facilitating the identification, prioritization, and implementation of research and other activities required for the responsible research necessary to develop, use, and oversee nanotechnology; 3) Promoting communication of information related to research on environmental, health, and safety implications of nanotechnology; 4) Adaptively managing (i.e., coordinating, reviewing, and revising) the interagency EHS research strategy (EHS Strategy Document); 5) Assisting in developing information and strategies as a basis for drafting guidance in the safe handling and use of nanomaterials and products; 6) With input from NSET and other interagency groups, supporting the development of tools and methods to identify, prioritize, and manage strategies for specific research to enable risk analysis and regulatory decision-making for nanomaterials and products incorporating nanomaterials; 7) Supporting developed of nanotechnology standards, including nomenclature and terminology, by consensus-based Nanotechnology Standards; and 8) Working with international organizations and governments to share information on and to develop strategies for nanotechnology environmental, health, and safety research.
|
|
NAPA Clinical Care Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ASPE, ACL, AHRQ, CDC, CMS, HRSA
|
NIA, NINDS
|
Subcommittee of the Advisory Council on Alzheimer's Research, Care, and Services, focused on clinical care
|
|
NAPA Federal Subgroup
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, ASPE, CDC, CMS, FDA, HRSA, IHS
|
NIA, NINDS
|
This informal group of federal staff meets quarterly, in advance of the meetings of the Alzheimer’s Council for Alzheimer’s Research, Care, and Services, to exchange information on federal activities in the Alzheimer’s disease space and foster collaborations across agencies. From 2014-2021, NIA facilitated these meetings and set the focus on research opportunities; starting in 2022, HHS/ASPE will coordinate these meetings and promote discussion across all NAPA goals, including those related to research, care, supports, and risk reduction.
|
|
NAPA Long-term Supports and Services (LTSS) Subcommitee
|
Committee, Work group, Advisory group, or Task Force
|
ASPE, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIA, NINDS
|
Subcommittee of the Advisory Council on Alzheimer's Research, Care, and Services, focused on LTSS
|
|
NAPA Research Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ASPE, AHRQ, CDC, CMS, FDA
|
NIA, NINDS
|
Subcommittee of the Advisory Council on Alzheimer's Research, Care, and Services, focused on research advances
|
|
NAPA Risk Reduction Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
ASPE, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIA, NINDS
|
Subcommittee of the Advisory Council on Alzheimer's Research, Care, and Services, focused on risk reduction
|
|
NASA-NIH Collaboration on Space-Related Health Research
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIAMS
|
N/A
|
|
NASA-NIH Scientific Potential/Actual Collaborative Efforts (SPACE) Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OASH
|
NCATS, NCI, NEI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIMH, NINDS, NLM, OD/DPCPSI/OBSSR
|
The NIH-NASA Scientific Potential/Actual Collaborative Efforts (SPACE) Group is an integral part of the NIH-NASA collaboration that meets quarterly to discuss, share and brainstorm biomedical research activities that are of relevance to human and astronaut heath. Its goals are to explore areas of potential synergy for biomedical scientific research that fulfills the mandates of both NIH and NASA, facilitate communications among researchers to instigate and support collaborative efforts, and explore possibilities for joint efforts between NIH and NASA to support research into synergistic biomedical interest areas and implement appropriate joint exercises.
|